Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy
International Ophthalmology · 2025
DOI: 10.1007/s10792-025-03481-x ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Ophthalmology, 2025. Verfasst von Xinli Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Harbin 242 Hospital, 3 Weijian Road, Pingfang District, Harbin, China. maxl_dr@163.com. Hauptthemen laut MEDLINE: Visual Acuity, Recombinant Fusion Proteins, Choroid, Polyps. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To compare the efficacy and safety of the 3+ pro re nata (PRN) and 3+ treat-and-extend (TAE) regimens of intravitreal conbercept for treating polypoidal choroidal vasculopathy (PCV). METHODS: This retrospective, single-center study included 106 treatment-naïve PCV patients who received intravitreal conbercept injections between March 2019 and September 2023. Patients were divided into two groups based on post-loading regimens: 3+PRN (65 patients) or 3+TAE (41 patients). All patients received three initial monthly injections. The 3+PRN group received additional injections as needed, while the 3+TAE group had treatment intervals adjusted based on lesion activity and visual acuity stability. Outcomes were assessed over 12 months, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, polyp regression, number of injections, and follow-up visits. RESULTS: Both groups showed significant improvements in BCVA from baseline to month 12 (3+TAE: 53.9 ± 16.5-61.4 ± 10.9 letters; 3+PRN: 54.6 ± 15.8-60.7 ± 11.5 letters; both P 0.05). CRT and PED height decreased significantly in both groups (P < 0.001), with no intergroup differences. Polypoidal lesion regression rates were similar at month 12 (3+TAE: 43.9%, 3+PRN: 44.6%; P = 0.964). The 3+PRN group required fewer injections (7.4 ± 0.7 vs. 8.2±1.6; P = 0.003) but more follow-up visits (12.6 ± 1.4 vs. 10.7 ± 1.2; P < 0.001) compared to the 3+TAE group. No ocular or systemic complications were reported in either group. CONCLUSIONS: Both the 3+PRN and 3+TAE conbercept regimens are effective and safe for treating PCV, demonstrating similar improvements in visual and anatomical outcomes. The 3+TAE regimen requires more injections but fewer follow-up visits, which may enhance patient adherence by reducing clinic visits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Harbin 242 Hospital, 3 Weijian Road, Pingfang District, Harbin, China. maxl_dr@163.com.
- Department of Ophthalmology, Harbin 242 Hospital, 3 Weijian Road, Pingfang District, Harbin, China.
Zitieren
APA
Ma, X., Han, D., Gao, J., Xu, Z., Qu, X., & Fu, Y. (2025). Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy. International Ophthalmology. https://doi.org/10.1007/s10792-025-03481-x
Vancouver
Ma X, Han D, Gao J, Xu Z, Qu X, Fu Y. Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy. International Ophthalmology. 2025. doi:10.1007/s10792-025-03481-x
BibTeX
@article{Ma2025,
author = {Ma, Xinli and Han, Dan and Gao, Jiayue and Xu, Ziwei and Qu, Xin and Fu, Yue},
title = {Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy},
journal = {International Ophthalmology},
year = {2025},
doi = {10.1007/s10792-025-03481-x}
}
EUVIMED